Induction of Proteasomal Activity in Mammalian Cells by Lifespan-extending tRNA Synthetase Inhibitors
AssigneeUNM Rainforest Innovations
InventorsMARK A. McCORMICK, BLAISE L. MARINER
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for treating, delaying, inhibiting, ameliorating or reducing the likelihood of neurodegenerative disease in a patient in need or at risk using tRNA synthetase inhibitors including borrelidin, mupirocin, tavaborole, halofuginone, LysRS-IN-2, REP 3132 (CRS-3132), REP8839 and mixtures thereof, among others as described herein.
Claims12
A method of treating, inhibiting, ameliorating, delaying the onset of or reducing the likelihood of a neurodegenerative disease in a patient in need or at risk comprising administering at least one tRNA synthetase inhibitor to the patient.
A pharmaceutical composition comprising an effective amount of a tRNA synthetase inhibitor and at least one additional bioactive agent.
Dependencies are inferred from the claim text.